Antidiabetic drugs for IBD: a long but promising road ahead for drug repositioning to target intestinal inflammation

J Gastroenterol. 2023 Jun;58(6):598-599. doi: 10.1007/s00535-023-01983-y. Epub 2023 Mar 24.

Authors

Shinichiro Shinzaki¹, Toshiyuki Sato², Hirokazu Fukui²

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, 663-8501, Japan. sh-shinzaki@hyo-med.ac.jp.
² Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, 663-8501, Japan.

PMID: 36961556
DOI: 10.1007/s00535-023-01983-y

No abstract available

Keywords: DPP-4; GLP-1; GLP-2; Inflammatory bowel disease; Metformin.

Publication types

Editorial

MeSH terms

Diabetes Mellitus, Type 2*
Dipeptidyl-Peptidase IV Inhibitors*
Drug Repositioning
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Inflammation / drug therapy
Inflammatory Bowel Diseases* / drug therapy

Substances

Hypoglycemic Agents
Dipeptidyl-Peptidase IV Inhibitors